Insights From Matrix Metalloproteinase-2 Genotypes to Decipher the Genetic Architecture of Bladder Cancer Risk

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Bladder cancer (BLCA) is a significant global health concern, with rising incidence in Taiwan.
• Genetic predisposition, alongside environmental factors like smoking, contributes to BLCA development.
• Matrix metalloproteinase-2 (MMP-2), involved in extracellular matrix remodeling, is implicated in BLCA progression.

Purpose of the Study:

• To investigate the association between two MMP-2 promoter polymorphisms (rs243865 and rs2285053) and BLCA susceptibility in a Taiwanese population.
• To explore potential correlations between these MMP-2 variants and BLCA aggressiveness.

Main Methods:

• A case-control study involving 375 BLCA patients and 375 controls.
• Genotyping using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).
• Logistic regression analysis to assess associations with BLCA risk, adjusting for confounders and performing stratified analyses.

Main Results:

• The MMP-2 rs2285053 polymorphism showed a significant allelic association with increased BLCA risk (OR=1.33, p=0.0263).
• The rs243865 polymorphism was linked to an elevated risk in younger individuals (≤55 years) with the CT genotype (OR=2.48, p=0.0028) and muscle-invasive BLCA with the TT genotype (OR=3.68, p=0.0001).
• In smokers, both CT and TT genotypes of rs2285053 were associated with higher BLCA risk (OR=1.68, p=0.0214 and OR=4.01, p=0.0045).

Conclusions:

• MMP-2 rs2285053 and rs243865 polymorphisms may influence bladder cancer susceptibility and aggressiveness.
• These genetic variants could potentially serve as biomarkers for personalized risk assessment in BLCA.
• Further validation in larger, multiethnic cohorts is warranted.